Registry platform for patients with blood cancers in Germany
Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2950 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Locations | 1 site (Freiburg im Breisgau) |
| Trial ID | NCT06043011 on ClinicalTrials.gov |
What this trial studies
The RUBIN project aims to establish a national, prospective, longitudinal registry to collect uniform data on patients with hematological malignancies in Germany. This observational study will document patient characteristics, treatment regimens, and disease progression while also gathering patient-reported outcomes. The registry will analyze the effectiveness of various treatments and identify unmet needs in routine care. Additionally, it will create a decentralized biobank for future research.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of specific non-Hodgkin lymphomas.
Not a fit: Patients who have not received systemic therapy for their lymphoid malignancy will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could improve treatment strategies and patient outcomes for individuals with hematological malignancies.
How similar studies have performed: Other similar registry studies have shown success in improving treatment outcomes and understanding disease progression in hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of the respective NHL * If patient is alive: signed written informed consent * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment. * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment. Exclusion Criteria: * No systemic therapy for respective lymphoid malignancy.
Where this trial is running
Freiburg im Breisgau
- Praxis für Interdisziplinäre Hämatologie und Onkologie — Freiburg im Breisgau, Germany (Recruiting)
Study contacts
- Study coordinator: Martina Jänicke, Dr.
- Email: rubin@iomedico.com
- Phone: +4976115242
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.